KGOP01

KGOP01 (H-Dmt-d-Arg-Aba-β-Ala-NH2) is a synthetic peptide derivative which acts as a potent agonist of opioid receptors and has analgesic effects.^[1] It was originally derived from modification of dermorphin, a naturally occurring opioid peptide secreted by some species of South American frogs.^[1]

Other names2,6-Dimethyl-L-tyrosyl-N-[(4S)-2-(3-amino-3-oxopropyl)-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl]-D-argininamide

PubChem CID

• 118731120

ChemSpider

• 58988148

ChEMBL

• ChEMBL3408737

Quick facts Clinical data, Other names ...

KGOP01

Clinical data
Other names	2,6-Dimethyl-L-tyrosyl-N-[(4S)-2-(3-amino-3-oxopropyl)-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl]-D-argininamide
Identifiers
IUPAC name (2R)-2-[[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(4S)-2-(3-amino-3-oxopropyl)-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]-5-(diaminomethylideneamino)pentanamide
PubChem CID	118731120
ChemSpider	58988148
ChEMBL	ChEMBL3408737
Chemical and physical data
Formula	C30H42N8O5
Molar mass	594.717 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H]2CC3=CC=CC=C3CN(C2=O)CCC(=O)N)N)C)O
InChI InChI=1S/C30H42N8O5/c1-17-12-21(39)13-18(2)22(17)15-23(31)27(41)36-24(8-5-10-35-30(33)34)28(42)37-25-14-19-6-3-4-7-20(19)16-38(29(25)43)11-9-26(32)40/h3-4,6-7,12-13,23-25,39H,5,8-11,14-16,31H2,1-2H3,(H2,32,40)(H,36,41)(H,37,42)(H4,33,34,35)/t23-,24+,25-/m0/s1 Key:VBTIGXSUDIFYPI-GVAUOCQISA-N

Close

While numerous opioid peptides are known and widely used in scientific research, such as DAMGO and DADLE, these are rapidly metabolised in the body and fail to cross the blood-brain barrier, and so do not produce centrally mediated analgesic effects.^[1] KGOP01 on the other hand contains several unnatural amino acids and is both metabolically stable and able to enter the brain, resulting in potent analgesic effects in animal studies.^[1]

Because it is a peptide, it can be readily hybridised with other peptide ligands and so has been widely used to produce hybrid compounds combining opioid activity with activity at receptors for neuropeptides such as nociceptin, neurokinin, neurotensin and neuropeptide FF, which may lead to the development of improved opioid analgesics with reduced side effects.^{[2][3][4][5][6]}